The average 12-month target price among brokers that have issued a report on the stock in the last year is $15.82. Boston Scientific has a one-year low of $11.10 and a one-year high of $15.28. The company has a market cap of $19.474 billion.
Additionally, Boston Scientific Executive Vice President Joseph Michael Fitzgerald sold 61,208 shares of the stock on the open market in a transaction on Feb. 10, for a total value of approximately $897,309, according to the report.
More articles on GI/endoscopy:
Male & female active physicians: 70 statistics by specialty
Opinion: Advances in HCV treatment underutilized due to barriers
Chromoendoscopy could boost ADR in Lynch syndrome
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.